MP24-04 LONG-TERM OUTCOMES OF PHASE 1 STUDY ON CYTOREDUCTIVE RADICAL PROSTATECTOMY: IS CURE POSSIBLE?

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-04 LONG-TERM OUTCOMES OF PHASE 1 STUDY ON CYTOREDUCTIVE RADICAL PROSTATECTOMY: IS CURE POSSIBLE? Joshua Sterling, Arnav Srivastava, Bertram Yuh, Seok Soo Byun, Shigeo Horie, and Isaac Kim Joshua SterlingJoshua Sterling More articles by this author , Arnav SrivastavaArnav Srivastava More articles by this author , Bertram YuhBertram Yuh More articles by this author , Seok Soo ByunSeok Soo Byun More articles by this author , Shigeo HorieShigeo Horie More articles by this author , and Isaac KimIsaac Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Roughly 4% of new prostate cancer (Pca) patients will be diagnosed with metastatic disease. Traditional treatments for these patients have focused on symptomatic relief and prevention of skeletal events. The dogma that there is no role for surgery in this population has started to be questioned. Here we report long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. METHODS: This is a multicenter phase 1 trial (NCT02458716). The major inclusion criteria was biopsy proven Pca with evidence of metastasis by MRI, CT, bone scan, or histologic confirmation. Primary end point was the major complication rate. Secondary outcomes were biochemical progression and overall survival. RESULTS: The patient characteristics of the 33 patients are included in this analysis are shown in table 1. With the median follow-up of 46 months, 25 out of the 33 patients (75%) are still alive at time of last contact. Kaplan Meier curve for overall survival is seen in figure 1. 15 patients still have an undetectable PSA. Among these men, seven were switched to intermittent androgen deprivation therapy and five remain free of any evidence of disease after more than two years off all systemic therapy and normalization of testosterone. Long term pad-free rate was 30.3%. CONCLUSIONS: Overall survival with a median follow-up of 46 months was 75% following cytoreductive radical prostatectomy. Importantly, 15% remain free of any evidence of disease off all systemic therapy for more than two years with normalization of testosterone. This observation suggest that the combination of surgery with systemic therapy may be curative in a minority of men who present with metastatic prostate cancer. However, long-term continence rate was only 30.3%. Source of Funding: This work is supported in part by the cancer center support grant from the National Cancer Institute (P30CA072720) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e412-e413 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joshua Sterling More articles by this author Arnav Srivastava More articles by this author Bertram Yuh More articles by this author Seok Soo Byun More articles by this author Shigeo Horie More articles by this author Isaac Kim More articles by this author Expand All Advertisement Loading ...